Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Abbott Laboratories (ABT), Boston Scientific Corporation (BSX), Johnson & Johnson (JNJ): Blame Obamacare for the Medical-Device Sales Slump?

3 High-Yield Pharma Stocks With Major CatalystsHas anyone noticed a common theme among the first-quarter results for many of the big medical-device companies? In case you missed earnings announcements from Abbott Laboratories (NYSE:ABT), Boston Scientific Corporation (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), Johnson & Johnson (NYSE:JNJ), or Stryker Corporation (NYSE:SYK), the following chart shows how their medical-device business fared during the quarter.

Abbott Laboratories (ABT), Boston Scientific Corporation (BSX), Johnson & Johnson (JNJ): Blame Obamacare for the Medical-Device Sales Slump?

Source: Company SEC Filings

Oh, wait — you don’t see a trend here? Actually, there is one. We just have to dig a little deeper to uncover it.

Hidden trend
Let’s start with J&J. Yes, the big company’s medical-device unit saw year-over-year sales growth of 10.2%. That’s great news, right? Not really.

These sales included the impact of J&J’s acquisition of Synthes. That impact: 14% worldwide sales growth. In other words, J&J’s medical-device sales actually shrank in the first quarter excluding this acquisition.

Edwards Lifesciences Corp (NYSE:EW) and Stryker Corporation (NYSE:SYK) both reported positive year-over-year sales growth for the first quarter, although Stryker’s numbers look relatively weak. Still, up is better than down. But notice how this growth compares with the two companies’ numbers over the past five years.

Abbott Laboratories (ABT), Boston Scientific Corporation (BSX), Johnson & Johnson (JNJ): Blame Obamacare for the Medical-Device Sales Slump?

SYK Revenue Quarterly YoY Growth data by YCharts

Unfortunately, the chart doesn’t reflect Stryker Corporation (NYSE:SYK)’s just-reported first-quarter year-over-year growth of 1.3%. However, if you mentally plug that recent figure into the picture, you’ll see something in common between the two companies. While they both grew sales, those growth rates caused the first quarter to be one of the two worst quarters since 2009 when the economy began emerging from the huge financial crisis from the previous year.

What these figures don’t show is that both companies missed analyst revenue expectations. Stryker Corporation (NYSE:SYK) fell short, although barely, with $2.19 billion in revenue versus the consensus analyst estimate of $2.2 billion.

Edwards, though, missed by a wider margin. The company reported first-quarter revenue of $497 million. Analysts expected nearly $519 million.Even worse for Edwards, the company cut its full-year sales forecasts. Shared plunged 22% on the news.

A culprit in common?
These large medical-device makers all experienced either sales declines or weak sales growth relative to the past. Could the common culprit be Obamacare?

It’s certainly no secret that several medical-device industry leaders predicted that Obamacare would hurt the industry. Stryker Corporation (NYSE:SYK) was one company that attributed large layoffs in part to the impact of the 2.3% excise tax the legislation imposed.

There’s an old adage that says, “Tax what you want less of.” Some would argue that there’s no coincidence between the first quarter of the Obamacare medical-device excise tax and the weak sales numbers that these large companies experienced.

The problem at this point, though, is there isn’t any conclusive evidence that Obamacare caused this first-quarter sluggishness. One factor to consider is that there were fewer sales days in the first quarter of 2013 than there were in the same quarter of 2012. Each company also supplied varying reasons for sales weakness.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.